MIR-155 as a potential biomarker for disease severity in st-segment elevation myocardial infarction: insights from a university-affiliated cardiovascular center.
Ailyn Morales-Rentería, Amina Ruiz-Santos, Luis M Amezcua-Castillo, Jazmín A Guerra-López, Kietseé A Díaz-Domínguez, José L Sánchez-Gloria, Héctor González-Pacheco, Luis M Amezcua-Guerra
{"title":"MIR-155 as a potential biomarker for disease severity in st-segment elevation myocardial infarction: insights from a university-affiliated cardiovascular center.","authors":"Ailyn Morales-Rentería, Amina Ruiz-Santos, Luis M Amezcua-Castillo, Jazmín A Guerra-López, Kietseé A Díaz-Domínguez, José L Sánchez-Gloria, Héctor González-Pacheco, Luis M Amezcua-Guerra","doi":"10.24875/RIC.24000189","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>MiR-155 plays a role in inflammatory pathways and cardiovascular diseases, though its relationship with inflammation, atherosclerosis, and outcomes in ST-elevation myocardial infarction (STEMI) is not well established.</p><p><strong>Objective: </strong>To investigate associations between miR-155 levels, inflammation, atherosclerotic burden, and major adverse cardiovascular events (MACE) in STEMI patients.</p><p><strong>Methods: </strong>Sixty-nine STEMI patients and 16 healthy controls were recruited from a specialized university-affiliated cardiovascular center. MiR-155 expression and serum interleukin (IL)-1β, IL-6, and tumor necrosis factor levels were measured. Patients were grouped into tertiles based on miR-155 expression. Clinical data, atherosclerotic burden (through cardiac catheterization), and in-hospital MACE were recorded.</p><p><strong>Results: </strong>MiR-155 levels were significantly lower in STEMI patients compared to controls (median 54.2, vs. 152.8 arbitrary units; p = 0.003). Higher miR-155 tertiles were associated with a greater prevalence of three-vessel occlusion (34% vs. 13% vs. 4%; p = 0.007) and increased incidence of pulmonary edema (13% vs. 0% vs. 0%; p = 0.030). No significant correlation was found between miR-155 and inflammatory or myocardial markers.</p><p><strong>Conclusion: </strong>Dysregulated miR-155 expression in STEMI patients may influence disease severity and MACE risk, independent of inflammation or myocardial damage markers.</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":" ","pages":""},"PeriodicalIF":1.4000,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista De Investigacion Clinica-Clinical and Translational Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.24875/RIC.24000189","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Background: MiR-155 plays a role in inflammatory pathways and cardiovascular diseases, though its relationship with inflammation, atherosclerosis, and outcomes in ST-elevation myocardial infarction (STEMI) is not well established.
Objective: To investigate associations between miR-155 levels, inflammation, atherosclerotic burden, and major adverse cardiovascular events (MACE) in STEMI patients.
Methods: Sixty-nine STEMI patients and 16 healthy controls were recruited from a specialized university-affiliated cardiovascular center. MiR-155 expression and serum interleukin (IL)-1β, IL-6, and tumor necrosis factor levels were measured. Patients were grouped into tertiles based on miR-155 expression. Clinical data, atherosclerotic burden (through cardiac catheterization), and in-hospital MACE were recorded.
Results: MiR-155 levels were significantly lower in STEMI patients compared to controls (median 54.2, vs. 152.8 arbitrary units; p = 0.003). Higher miR-155 tertiles were associated with a greater prevalence of three-vessel occlusion (34% vs. 13% vs. 4%; p = 0.007) and increased incidence of pulmonary edema (13% vs. 0% vs. 0%; p = 0.030). No significant correlation was found between miR-155 and inflammatory or myocardial markers.
Conclusion: Dysregulated miR-155 expression in STEMI patients may influence disease severity and MACE risk, independent of inflammation or myocardial damage markers.
背景：MiR-155在炎症途径和心血管疾病中发挥作用，尽管其与炎症、动脉粥样硬化和st段抬高型心肌梗死（STEMI）结局的关系尚不清楚。目的：探讨STEMI患者miR-155水平、炎症、动脉粥样硬化负担和主要不良心血管事件（MACE）之间的关系。方法：从某大学附属心血管专科中心招募69例STEMI患者和16例健康对照。检测MiR-155表达、血清白细胞介素(IL)-1β、IL-6和肿瘤坏死因子水平。根据miR-155的表达将患者分组。记录临床资料、动脉粥样硬化负担（通过心导管）和住院MACE。结果：与对照组相比，STEMI患者的MiR-155水平显著降低(中位数为54.2，对152.8任意单位；P = 0.003)。较高的miR-155位数与较高的三支血管闭塞患病率相关(34% vs. 13% vs. 4%；P = 0.007)和肺水肿发生率增加(13% vs. 0% vs. 0%；P = 0.030)。miR-155与炎症或心肌标志物之间无显著相关性。结论：STEMI患者miR-155表达异常可能影响疾病严重程度和MACE风险，与炎症或心肌损伤标志物无关。
期刊介绍：
The Revista de Investigación Clínica – Clinical and Translational Investigation (RIC-C&TI), publishes original clinical and biomedical research of interest to physicians in internal medicine, surgery, and any of their specialties. The Revista de Investigación Clínica – Clinical and Translational Investigation is the official journal of the National Institutes of Health of Mexico, which comprises a group of Institutes and High Specialty Hospitals belonging to the Ministery of Health. The journal is published both on-line and in printed version, appears bimonthly and publishes peer-reviewed original research articles as well as brief and in-depth reviews. All articles published are open access and can be immediately and permanently free for everyone to read and download. The journal accepts clinical and molecular research articles, short reports and reviews.
Types of manuscripts:
– Brief Communications
– Research Letters
– Original Articles
– Brief Reviews
– In-depth Reviews
– Perspectives
– Letters to the Editor
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
